Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now includes information about Pembrolizumab as a treatment option for non-small-cell lung cancer, referencing a specific medical journal article.
    Difference
    0.5%
    Check dated 2025-03-11T04:24:00.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has removed a reference to Pembrolizumab for the treatment of non-small-cell lung cancer, which may impact the information available regarding this treatment option.
    Difference
    0.5%
    Check dated 2025-03-03T23:30:06.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page now includes information about Pembrolizumab as a treatment option for non-small-cell lung cancer, which is a significant addition to the core content.
    Difference
    2%
    Check dated 2025-02-24T20:42:49.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page has updated its core content by replacing a study on the safety and activity of an anti-PD-L1 antibody with a new randomized trial comparing preoperative chemotherapy plus surgery with surgery alone for non-small-cell lung cancer.
    Difference
    4%
    Check dated 2025-02-17T14:45:11.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page has removed information about Pembrolizumab for treating non-small-cell lung cancer and added a note regarding heavy traffic affecting NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-10T09:47:30.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.14.2, while the previous revision v2.14.1 has been removed along with two significant medical trial references.
    Difference
    2%
    Check dated 2025-02-03T07:36:37.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.